• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Intervacc

1.30 SEK

-0.76 %

Less than 1K followers

IVACC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.76 %
+14.84 %
+75.68 %
+40.69 %
+47.73 %
+37.71 %
-80.45 %
-97.99 %
-76.50 %

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

Read more
Market cap
443.06M SEK
Turnover
705.31K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Forum discussions
Intervacc Q2: Net sales 1.9 M (SEK) Operating loss -18 M Net loss for the period -18 M To put it plainly, a total fiasco. International sales of the miracle vaccine are a ridiculous 160 thousand euros, which is on the same level as the turnover of some local car repair shop in Kajaani...
8/31/2023, 6:45 AM
by pt99659
7
Hello, a brand new interview with Intervacc’s new CEO Carl-Johan Dalsgaard about, among other things, the situation in the American market, challenges that must be overcome, and future prospects.
3/19/2026, 1:31 PM
by Isa Hudd
2
Its time will surely come. The product is very good in terms of its effectiveness; its need is just somewhat relative. Adoption takes its time. Sales are indeed slowly growing, but USA approvals are needed (as always in pharma) to truly make a profit. That will still take a couple...
10/14/2025, 5:19 PM
by Clark kent
2
Offering terms published. In a week, shares can be subscribed at a price of 4.10 SEK. Dilution 33%
5/16/2023, 8:37 AM
by pt99659
2
US approval will decide the fate of this stock. The product is good, but local trials still need to be executed correctly to obtain the approval. Additional expertise has been recruited to the management team and the board; let’s see how they perform. It will likely take a couple...
4/16/2026, 3:52 PM
by Clark kent
1
It’s interesting that the commercialization project for the vaccine product continues, with more countries in the distribution scope, etc. In itself, the company’s stock price is at rock bottom, if not below the basement floor. Inderes Intervacc and Dechra extend distribution agreement...
10/14/2025, 3:08 PM
by veronmaksaja
1
It is worth noting that the customer is conservative. The product is very good; the marketing work just needs to be done. For those with a risk tolerance, there are good opportunities to buy the stock. Those with lower risk tolerance should wait for US marketing authorization; there...
8/31/2023, 3:08 PM
by Clark kent
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.8.
2026

Interim report Q2'26

12.11.
2026

Interim report Q3'26

17.2.
2027

Annual report '26

Press release6/4/2026, 8:30 AM

Redeye: Redeye initiates coverage of Intervacc

Intervacc
Press release5/22/2026, 9:38 AM

DNB Carnegie Access: Intervacc: Positive results

Intervacc
Regulatory press release5/22/2026, 6:30 AM

Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials

Intervacc

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/15/2026, 8:24 AM

DNB Carnegie Access: Intervacc: US progress, while European sales still soft – Q1 review

Intervacc
Regulatory press release5/15/2026, 6:30 AM

Emil Billbäck appointed new Chair of the Board of Intervacc

Intervacc
Regulatory press release5/13/2026, 2:15 PM

Report from Annual General Meeting in Intervacc

Intervacc
Regulatory press release5/13/2026, 6:30 AM

Interim report January - March 2026

Intervacc
Regulatory press release5/12/2026, 11:00 AM

Intervacc strengthens management team for future growth

Intervacc
Regulatory press release5/4/2026, 6:30 AM

Intervacc: International Awareness Initiative Against Strangles

Intervacc
Regulatory press release4/23/2026, 6:30 AM

Intervacc brings together leading US and European experts to jointly tackle strangles

Intervacc
Regulatory press release4/16/2026, 6:30 AM

Intervacc: Unprecedented decision opens the way for the launch of Strangvac in Iceland

Intervacc
Regulatory press release4/14/2026, 6:30 AM

Intervacc publishes the 2025 Annual Report

Intervacc
Regulatory press release4/10/2026, 3:45 PM

Notice of Annual General Meeting in Intervacc AB (publ)

Intervacc
Press release3/20/2026, 9:30 AM

DNB Carnegie Access: Intervacc: Highly promising data presented

Intervacc
Regulatory press release3/19/2026, 10:32 PM

Intervacc announces breakthrough protection against Streptococcus suis infection in piglets

Intervacc
Press release3/9/2026, 7:30 AM

Intervacc presents to the capital market on three occasions in March

Intervacc
Press release2/18/2026, 5:39 AM

DNB Carnegie Access: Intervacc: Growth story remains despite weak quarter – Q4 review

Intervacc
Regulatory press release2/17/2026, 7:30 AM

Intervacc: Year-end report January - December 2025

Intervacc
Press release2/6/2026, 6:38 AM

DNB Carnegie Access: Intervacc: New CEO announced

Intervacc
Regulatory press release2/5/2026, 6:15 PM

Intervacc announces change of CEO

Intervacc